ACY-1215 for Relapsed/Refractory Lymphoid Malignancies
Condition(s):Lymphoma; Lymphoid MalignanciesLast Updated:February 10, 2020Completed
Hide Studies Not Open or Pending
Condition(s):Lymphoma; Lymphoid MalignanciesLast Updated:February 10, 2020Completed
Condition(s):Metastatic Breast Cancer; Breast CarcinomaLast Updated:January 7, 2021Completed
Condition(s):Multiple MyelomaLast Updated:February 15, 2024Active, not recruiting
Condition(s):Multiple MyelomaLast Updated:April 6, 2017Completed
Condition(s):Multiple MyelomaLast Updated:November 21, 2019Completed
Condition(s):Recurrent Chronic Lymphoid LeukemiaLast Updated:December 29, 2023Active, not recruiting
Condition(s):Multiple MyelomaLast Updated:February 23, 2022Completed
Condition(s):HealthyLast Updated:September 11, 2014Completed
Condition(s):Painful Diabetic Peripheral NeuropathyLast Updated:September 21, 2023Completed
Condition(s):Non-Resectable Cholangiocarcinoma; Recurrent Cholangiocarcinoma; Stage III Extrahepatic Bile Duct Cancer; Stage III Intrahepatic Cholangiocarcinoma; Stage IIIA Hilar Cholangiocarcinoma; Stage IIIB Hilar Cholangiocarcinoma; Stage IVA Extrahepatic Bile Duct Cancer; Stage IVA Hilar Cholangiocarcinoma; Stage IVA Intrahepatic Cholangiocarcinoma; Stage IVB Extrahepatic Bile Duct Cancer; Stage IVB Hilar Cholangiocarcinoma; Stage IVB Intrahepatic Cholangiocarcinoma; Unresectable Extrahepatic Bile Duct CarcinomaLast Updated:May 30, 2017Withdrawn
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.